[{"address1": "321 Summer Street", "address2": "Suite 400", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "(857) 330-4340", "website": "https://www.inozyme.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 59, "companyOfficers": [{"maxAge": 1, "name": "Dr. Douglas A. Treco Ph.D.", "age": 65, "title": "CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 591875, "exercisedValue": 0, "unexercisedValue": 116098}, {"maxAge": 1, "name": "Mr. Axel  Bolte M.B.A., M.Sc.", "age": 51, "title": "Co-Founder, Senior Advisor & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 1158083, "exercisedValue": 0, "unexercisedValue": 1257688}, {"maxAge": 1, "name": "Mr. Sanjay S. Subramanian M.B.A., M.S.", "age": 46, "title": "Senior VP, CFO, Principal Accounting Officer & Corporate Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 626233, "exercisedValue": 0, "unexercisedValue": 47925}, {"maxAge": 1, "name": "Dr. Matthew  Winton Ph.D.", "age": 45, "title": "Senior VP & COO", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 526431, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Demetrios  Braddock M.D., Ph.D.", "title": "Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Soojin  Kim Ph.D.", "title": "Senior VP & Chief Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Thompson M.A., M.S., Ph.D.", "title": "Senior VP, Chief Scientific Officer & Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stefan  Riley", "title": "Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gayle  Gironda", "title": "Senior VP & Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yves  Sabbagh Ph.D.", "title": "Chairman of Scientific Advisory Board & Senior VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.67, "open": 5.62, "dayLow": 5.6075, "dayHigh": 5.86, "regularMarketPreviousClose": 5.67, "regularMarketOpen": 5.62, "regularMarketDayLow": 5.6075, "regularMarketDayHigh": 5.86, "beta": 1.524, "forwardPE": -3.630573, "volume": 199643, "regularMarketVolume": 199643, "averageVolume": 349529, "averageVolume10days": 295630, "averageDailyVolume10Day": 295630, "bid": 5.69, "ask": 5.72, "bidSize": 400, "askSize": 200, "marketCap": 352576352, "fiftyTwoWeekLow": 2.689, "fiftyTwoWeekHigh": 7.795, "fiftyDayAverage": 4.7836, "twoHundredDayAverage": 4.67695, "currency": "USD", "enterpriseValue": 233058400, "floatShares": 37908149, "sharesOutstanding": 61855500, "sharesShort": 4259564, "sharesShortPriorMonth": 2727965, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.0689, "heldPercentInsiders": 0.00519, "heldPercentInstitutions": 0.92727, "shortRatio": 11.08, "shortPercentOfFloat": 0.0747, "impliedSharesOutstanding": 61855500, "bookValue": 1.922, "priceToBook": 2.9656606, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -77112000, "trailingEps": -1.35, "forwardEps": -1.57, "pegRatio": -0.25, "enterpriseToEbitda": -2.835, "52WeekChange": 0.103581786, "SandP52WeekChange": 0.19608545, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "INZY", "underlyingSymbol": "INZY", "shortName": "Inozyme Pharma, Inc.", "longName": "Inozyme Pharma, Inc.", "firstTradeDateEpochUtc": 1595597400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f627b06e-ce15-3126-896c-1db8a4222086", "messageBoardId": "finmb_568596329", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.7, "targetHighPrice": 40.0, "targetLowPrice": 14.0, "targetMeanPrice": 19.43, "targetMedianPrice": 15.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 166152992, "totalCashPerShare": 2.686, "ebitda": -82213000, "totalDebt": 46635000, "quickRatio": 13.393, "currentRatio": 14.052, "debtToEquity": 39.243, "returnOnAssets": -0.32558, "returnOnEquity": -0.69413, "freeCashflow": -52528376, "operatingCashflow": -77436000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-25"}]